Canaccord Genuity Maintains Buy on Cara Therapeutics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Cara Therapeutics (NASDAQ:CARA) but lowers the price target from $11 to $10.

March 06, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Cara Therapeutics but lowers the price target from $11 to $10.
The reduction in price target by Canaccord Genuity could have a mixed impact on CARA's stock price. While maintaining a Buy rating indicates a positive outlook on the company, lowering the price target might signal a tempered expectation for the stock's short-term performance. Investors might view this adjustment as a cautious stance from the analyst, potentially leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100